Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sartorius Stedim BiotechCHIX:DIMP 82 Shiller PE Ratio is 45.77 as of Sep. 15, 2026, which is 11% below its 10-year median of 51.55. GuruFocus rates CHIX:DIMP with a GF Score™ of 82/100 and a GF Value™ of €202.88 (Fairly Valued). The stock has 5 warning signs investors should review. Among 313 Medical Devices & Instruments companies, Sartorius Stedim Biotech ranks worse than 81.15% on this metric.
The historical rank and industry rank for Sartorius Stedim Biotech's Shiller PE Ratio or its related term are showing as below:
CHIX:DIMp'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 37.37 Med: 51.55 Max: 120.93
Current: 45.46
During the past years, Sartorius Stedim Biotech's highest Shiller PE Ratio was 120.93. The lowest was 37.37. And the median was 51.55.
CHIX:DIMp's Shiller PE Ratio is ranked worse than 81.15% of 313
companies
in the Medical Devices & Instruments industry
Industry Median: 24.65
vs CHIX:DIMp: 45.46
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Sartorius Stedim Biotech's adjusted earnings per share data for the three months ended in Jun. 2026 was €0.956. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is €4.03 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Sartorius Stedim Biotech (CHIX:DIMp) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Sartorius Stedim Biotech Shiller PE Ratio Related Terms
Sartorius Stedim Biotech Shiller PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:DIMP vs ISRG, BDX, RMD: Shiller PE Ratio Comparison
For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius Stedim Biotech Shiller PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Sartorius Stedim Biotech's Shiller PE Ratio falls into.
Sartorius Stedim Biotech Shiller PE Ratio Calculation
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Sartorius Stedim Biotech (CHIX:DIMP) has a Shiller PE Ratio of 45.77 as of Sep. 15, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Sartorius Stedim Biotech and its competitors. This is 11% below median its historical median of 51.55. Over the past decade, Sartorius Stedim Biotech's Shiller PE Ratio has ranged from 37.37 to 120.93. According to the industry distribution chart, Sartorius Stedim Biotech ranks #254 out of 313 companies in the Medical Devices & Instruments industry, placing it in the top 81.2%.
Is Sartorius Stedim Biotech's Shiller PE Ratio too high?
Sartorius Stedim Biotech's current Shiller PE Ratio of 45.77 is 11% below median its 10-year median of 51.55. Over the past 10 years, this metric has ranged from a low of 37.37 to a high of 120.93. The Medical Devices & Instruments industry median Shiller PE Ratio is 24.65. Sartorius Stedim Biotech's value of 45.77 is 85.7% above this industry median. Based on the distribution chart, Sartorius Stedim Biotech ranks #254 out of 313 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sartorius Stedim Biotech has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Shiller PE Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius Stedim Biotech ranks #254 out of 313 companies for Shiller PE Ratio. This places Sartorius Stedim Biotech in the lower half of its industry. The industry median Shiller PE Ratio is 24.65. Sartorius Stedim Biotech's value of 45.77 is 85.7% above this benchmark. Historically, Sartorius Stedim Biotech's own Shiller PE Ratio has ranged from 37.37 to 120.93 over the past decade. While the company's 10-year median is 51.55 vs. the industry median of 24.65, Sartorius Stedim Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Medical Devices & Instruments company?
The median Shiller PE Ratio among Medical Devices & Instruments companies is 24.65, based on 313 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius Stedim Biotech's current Shiller PE Ratio of 45.77 is 85.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Sartorius Stedim Biotech and its competitors. For the Medical Devices & Instruments industry, the median Shiller PE Ratio is 24.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius Stedim Biotech's current Shiller PE Ratio is 45.77, which is 11% below median its own 10-year median of 51.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Fairly Valued. The stock's GF Value™ is €202.88, compared to a current price of €184.45 — trading 9.1% below its estimated fair value. The current Shiller PE Ratio is 45.77, which is 11% below median its 10-year median of 51.55 and 85.7% above the Medical Devices & Instruments industry median of 24.65. Sartorius Stedim Biotech's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current Shiller PE Ratio is 45.77 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of €184.45 is trading 9.1% below its estimated GF Value™ of €202.88.
GuruFocus considers Sartorius Stedim Biotech to be Fairly Valued.
Key valuation signals for CHIX:DIMP:
Shiller PE Ratio: 45.77 (11% below median its 10-year median of 51.55)
GF Value™: €202.88 vs. price of €184.45 (9.1% below fair value)
Industry Position: 85.7% above the Medical Devices & Instruments median (#254 of 313)
No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
82GF Score
Get the complete analysis for CHIX:DIMP
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DIMP has been successfully added to your 
